Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 6/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | ILK | Q13418 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24938199 | 0.90 | EGFR (0.52) | EGFRGAKKDRHDAC3HDAC1 | |
| SCHEMBL22338293 | 0.86 | SRC (0.56) | EGFRKDRHDAC3HDAC1HDAC6 | |
| SCHEMBL28011751 | 0.75 | EGFR (0.54) | EGFRGAKKDRHDAC3HDAC1 | |
| SCHEMBL27941737 | 0.74 | EGFR (0.61) | EGFRGAKKDRKDM1AFLT1 | |
| SCHEMBL29755923 | 0.73 | EGFR (0.60) | EGFRGAKKDRKDM1AFLT1 | |
| SCHEMBL16660323 | 0.72 | EGFR (0.77) | EGFRGAKKDRHDAC3HDAC1 | |
| SCHEMBL7708517 | 0.72 | EGFR (0.77) | EGFRGAKKDRHDAC3HDAC1 | |
| SCHEMBL163465 | 0.72 | ENPP1 (0.71) | EGFRGAKKDRKDM1AFLT1 | |
| SCHEMBL471137 | 0.72 | KDM1A (0.57) | EGFRGAKKDRKDM1AFLT1 | |
| SCHEMBL29478510 | 0.72 | ENPP1 (0.71) | EGFRGAKKDRKDM1AFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | EGFR 659/4885GAK 2670/4885KDR 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.